<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="e4f1e75a-e315-00f1-a044-13b6d2dcbca4"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use EPHEDRINE SULFATE INJECTION safely and effectively. See full prescribing information for EPHEDRINE SULFATE INJECTION. <br/>
      <br/>EPHEDRINE SULFATE injection, for intravenous use <br/>
      <br/>Initial U.S. Approval: 2016 <br/>
      <br/>
   </title>
   <effectiveTime value="20230801"/>
   <setId root="1d1c41c1-8f5f-ee76-c890-4f1f2a3b2e96"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="802315887" root="1.3.6.1.4.1.519.1"/>
            <name>Dr. Reddy's Laboratories, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="650446243" root="1.3.6.1.4.1.519.1"/>
                        <name>Dr. Reddy's Laboratories Limited-FTO-9</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="43598-725" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="43598-725" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="pack"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="43598-725" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="66276d3f-1a76-55df-b479-fe9809d0ee94"/>
               <code code="48780-1" displayName="SPL PRODUCT DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20181224"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="43598-725"/>
                        <name>Ephedrine sulfate</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ephedrine sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="50"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="U6X61U5ZEG" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EPHEDRINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="GN83C131XS" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EPHEDRINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69" code="43598-725-11"/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="25"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="43598-725-25"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20211004"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA212649" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code codeSystem="1.0.3166.1.2.3" code="USA"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20211004"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <section>
                     <id root="b8753c99-37f4-8cb2-8126-7bcb5ee6392a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <effectiveTime value="20210929"/>
                     <component>
                        <observationMedia ID="MM436378465215">
                           <text>vial-label</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="vial-label.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM727051641174">
                           <text>logo</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="logo.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_0100">
               <id root="06ce9a04-429f-dc88-b9e2-b41c64236369"/>
               <code code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>1  INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.</paragraph>
               </text>
               <effectiveTime value="20230801"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ephedrine sulfate injection is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. (<linkHtml href="#s_0100">1</linkHtml>)</paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s_0200">
               <id root="90c1183b-4a25-4810-ef5b-7833f72a2053"/>
               <code code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>2  DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20220601"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Should be administered by trained healthcare providers (<linkHtml href="#s_0201">2.1</linkHtml>) </item>
                           <item>Ephedrine sulfate injection, 50 mg/mL, must be diluted before administration as an intravenous bolus dose. (<linkHtml href="#s_0201">2.1</linkHtml>)</item>
                           <item>Bolus intravenous injection: 5 to 10 mg as needed, not to exceed 50 mg. (<linkHtml href="#s_0200">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s_0201">
                     <id root="012f93cf-428b-92e0-c781-0a6a04a18064"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.1	General Dosage and Administration Instructions</title>
                     <text>
                        <paragraph>Ephedrine sulfate injection, 50 mg/mL must be diluted before administration as an intravenous bolus to achieve the desired concentration. Dilute with normal saline or 5% dextrose in water.</paragraph>
                        <paragraph>Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0202">
                     <id root="e1689343-a8d4-8e01-dcdf-10ab3eb0860a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.2	Dosing for the Treatment of Clinically Important Hypotension in the Setting of Anesthesia</title>
                     <text>
                        <paragraph>Ephedrine sulfate injection should be administered by trained healthcare providers.</paragraph>
                        <paragraph>The recommended dosages for the treatment of clinically important hypotension in the setting of anesthesia is an initial dose of 5 mg to 10 mg administered by intravenous bolus. Administer additional boluses as needed, not to exceed a total dosage of 50 mg.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Adjust dosage according to the blood pressure goal (i.e., titrate to effect).</item>
                        </list>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0203">
                     <id root="c0048bd6-e92e-bb82-1db4-d42613e36bf4"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.3	Prepare a 5 mg/mL Solution for Bolus Intravenous Administration</title>
                     <text>
                        <paragraph>For bolus intravenous administration, prepare a solution containing a final concentration of 5 mg/mL of ephedrine sulfate injection:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Withdraw 50 mg (1 mL of 50 mg/mL) of ephedrine sulfate injection  and dilute with 9 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection.</item>
                           <item>Withdraw an appropriate dose of the 5 mg/mL solution prior to bolus intravenous administration.</item>
                        </list>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_0300">
               <id root="9fa91502-0736-7f67-f65a-fc7bbecd7b1a"/>
               <code code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>3  DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Ephedrine sulfate injection, USP is a clear, colorless, sterile solution for intravenous injection available as :</paragraph>
                  <paragraph>single-dose 1 mL vial that contains 50 mg/mL ephedrine sulfate, equivalent to 38 mg/mL ephedrine base. </paragraph>
               </text>
               <effectiveTime value="20220601"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 50 mg/mL ephedrine sulfate in single-dose vial (<linkHtml href="#s_0300">3</linkHtml>)</paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s_0400">
               <id root="8d359266-e168-ab61-fbff-45344781c49c"/>
               <code code="34070-3" displayName="CONTRAINDICATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>4  CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None</paragraph>
               </text>
               <effectiveTime value="20220601"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (<linkHtml href="#s_0400">4</linkHtml>)</paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s_0500">
               <id root="b4f56dfb-d965-f95b-bf95-e700a06270e1"/>
               <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>5  WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20220601"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Pressor Effects with Concomitant Use with Oxytocic Drugs</content>: Pressor effect of sympathomimetic pressor amines is potentiated (<linkHtml href="#s_0501">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Tachyphylaxis and Tolerance</content>: Repeated administration of ephedrine may cause tachyphylaxis (<linkHtml href="#s_0502">5.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s_0501">
                     <id root="b7dc4ff2-d794-6ced-f398-ab1baa90eace"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.1	Pressor Effect with Concomitant Oxytocic Drugs</title>
                     <text>
                        <paragraph>Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine,  ergonovine) [<content styleCode="italics">see <linkHtml href="#s_0700">Drug Interactions (7)</linkHtml>
                           </content>]. Some of these patients experienced a stroke. Carefully monitor the blood pressure of individuals who have received both ephedrine and an oxytocic.</paragraph>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0502">
                     <id root="08c7310c-5785-576b-0fa9-adac0ca48883"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.2	Tolerance and Tachyphylaxis</title>
                     <text>
                        <paragraph>Data indicate that repeated administration of ephedrine can result in tachyphylaxis. Clinicians treating anesthesia-induced hypotension with ephedrine sulfate injection  should be aware of the possibility of tachyphylaxis and should be prepared with an alternative pressor to mitigate unacceptable responsiveness. </paragraph>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0503">
                     <id root="0183f1c0-04ab-ca6c-32c7-685c37b46706"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.3	Risk of Hypertension When Used Prophylactically</title>
                     <text>
                        <paragraph>When used to prevent hypotension, ephedrine has been associated with an increased incidence of hypertension compared with when ephedrine is used to treat hypotension.</paragraph>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_0600">
               <id root="8c0f901d-69dc-77db-34e5-069fadfe891e"/>
               <code code="34084-4" displayName="ADVERSE REACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>6  ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions associated with the use of ephedrine sulfate were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal disorders:</content> Nausea, vomiting </paragraph>
                  <paragraph>
                     <content styleCode="italics">Cardiac disorders:</content> Tachycardia, palpitations (thumping heart), reactive hypertension, bradycardia, ventricular ectopics, R-R variability</paragraph>
                  <paragraph>
                     <content styleCode="italics">Nervous system disorders:</content> Dizziness</paragraph>
                  <paragraph>
                     <content styleCode="italics">Psychiatric disorders:</content> Restlessness</paragraph>
               </text>
               <effectiveTime value="20220601"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions during treatment: nausea, vomiting, and tachycardia. (<linkHtml href="#s_0600">6</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories, Inc. at 1-888-375-3784 or FDA at 1-800-FDA-1088 or <content styleCode="italics">
                                 <linkHtml href="https://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                              </content>.</content>
                        </paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s_0700">
               <id root="d898be35-9984-bf0d-9fa3-78d51c8b94cd"/>
               <code code="34073-7" displayName="DRUG INTERACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>7  DRUG INTERACTIONS</title>
               <text>
                  <table styleCode="Noautorules" width="700">
                     <col align="left" width="25%"/>
                     <col align="left" width="75%"/>
                     <tbody>
                        <tr valign="top">
                           <td align="center" colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Interactions that Augment the Pressor Effect</content>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Oxytocin and oxytocic drugs</content>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovine). Some of these patients experienced a stroke. </td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">Carefully monitor the blood pressure of individuals who have received both ephedrine and an oxytocic.</td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Clonidine, propofol, monoamine oxidase inhibitors (MAOIs), atropine</content>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">These drugs augment the pressor effect of ephedrine.</td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">Carefully monitor the blood pressure of individuals who have received both ephedrine and any of these drugs.</td>
                        </tr>
                        <tr valign="top">
                           <td align="center" colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Interactions that Antagonize the Pressor Effect</content>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">These drugs antagonize the pressor effect of ephedrine.</td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">Carefully monitor the blood pressure of individuals who have received both ephedrine and any of these drugs.</td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Examples: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine</td>
                        </tr>
                        <tr valign="top">
                           <td align="center" colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Other Drug Interactions</content>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Guanethidine</content>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. </td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">Clinician should monitor patient for blood pressor response and adjust the dosage or choice of pressor accordingly.</td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Rocuronium</content>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">Ephedrine may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction.</td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">Be aware of this potential interaction. No treatment or other interventions are needed.</td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Epidural anesthesia</content>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">Ephedrine may decrease the efficacy of epidural blockade by hastening the regression of sensory analgesia. </td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">Monitor and treat the patient according to clinical practice.</td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Theophylline</content>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">Concomitant use of ephedrine may increase the frequency of nausea, nervousness, and insomnia.</td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">Monitor patient for worsening symptoms and manage symptoms according to clinical practice.</td>
                        </tr>
                        <tr valign="top">
                           <td colspan="2" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Cardiac glycosides</content>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Clinical Impact: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">Giving ephedrine with a cardiac glycoside, such as digitalis, may increase the possibility of arrhythmias.</td>
                        </tr>
                        <tr valign="top">
                           <td align="left" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="italics">Intervention: </content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">Carefully monitor patients on cardiac glycosides who are also administered ephedrine.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20220601"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Interactions that Augment Pressor Effect</content>: clonidine, oxytocin and oxytocic drugs, propofol, monoamine oxidase inhibitors (MAOIs), and atropine. Monitor blood pressure. (<linkHtml href="#s_0700">7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Interactions that Antagonize the Pressor Effect</content>: Antagonistic effects with α-adrenergic antagonists, β-adrenergic antagonists, reserpine, quinidine, mephentermine. Monitor blood pressure. (<linkHtml href="#s_0700">7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Guanethidine</content>: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. Monitor blood pressure and adjust the dosage of pressor accordingly.</item>
                           <item>
                              <content styleCode="underline">Rocuronium</content>: Ephedrine may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction. Be aware of this potential interaction. No treatment or other interventions are needed.</item>
                           <item>
                              <content styleCode="underline">Epidural anesthesia</content>: Ephedrine may decrease the efficacy of epidural blockade by hastening the regression of sensory analgesia. Monitor and treat the patient according to clinical practice.</item>
                           <item>
                              <content styleCode="underline">Theophylline</content>: Concomitant use of ephedrine may increase the frequency of nausea, nervousness, and insomnia. Monitor patient for worsening symptoms and manage symptoms according to clinical practice.</item>
                           <item>
                              <content styleCode="underline">Cardiac glycosides</content>: Giving ephedrine with a cardiac glycoside, such as digitalis, may increase the possibility of arrhythmias. Carefully monitor patients on cardiac glycosides who are also administered ephedrine.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s_0800">
               <id root="5c02aa63-af85-a83c-b5dc-4ec4b3ef41c3"/>
               <code code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>8  USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20220601"/>
               <component>
                  <section ID="s_0801">
                     <id root="07af65f3-87a7-637a-ba6d-b5ce9524ad44"/>
                     <code code="42228-7" displayName="PREGNANCY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.1  Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Available data from randomized studies, case series, and reports of ephedrine sulfate use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. However, there are clinical considerations due to underlying conditions <content styleCode="italics">(see Clinical Considerations)</content>. In animal reproduction studies, decreased fetal survival and fetal body weights were observed in the presence of maternal toxicity after normotensive pregnant rats were administered 60 mg/kg intravenous ephedrine sulfate (12 times the maximum recommended human dose (MRHD) of 50 mg/day). No malformations or embryofetal adverse effects were observed when pregnant rats or rabbits were treated with intravenous bolus doses of ephedrine sulfate during organogenesis at doses 1.9 and 7.7 times the MRHD, respectively <content styleCode="italics">[see data]. </content>
                        </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-associated maternal and/or embryofetal risk</content>
                        </paragraph>
                        <paragraph>Untreated hypotension associated with spinal anesthesia for cesarean section is associated with an increase in maternal nausea and vomiting. A decrease in uterine blood flow due to maternal hypotension may result in fetal bradycardia and acidosis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. These reports describe umbilical artery pH of ≤7.2 at the time of delivery<content styleCode="italics"> [see Clinical Pharmacology <linkHtml href="#s_1203">(12.3)</linkHtml>]</content>. Monitoring of the newborn for signs and symptoms of metabolic acidosis may be required. Monitoring of infant’s acid-base status is warranted to ensure that an episode of acidosis is acute and reversible.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Decreased fetal body weights were observed when pregnant rats were administered intravenous bolus doses of 60 mg/kg ephedrine sulfate (12 times the maximum recommended human dose (MRHD) of 50 mg based on body surface area) from Gestation Day 6 to 17. This dose was associated with evidence of maternal toxicity (decreased body weight of dams and abnormal head movements). No malformations or fetal deaths were noted at this dose. No effects on fetal body weight were noted at 10 mg/kg (1.9 times the MRHD of 50 mg).</paragraph>
                        <paragraph>No evidence of malformations or embryo-fetal toxicity were noted in pregnant rabbits administered intravenous bolus doses up to 20 mg/kg ephedrine sulfate (7.7 times the maximum recommended human dose (MRHD) of 50 mg based on body surface area) from Gestation Day 6 to 20. This dose was associated with expected pharmacological maternal effects (increased respiration rate, dilated pupils, piloerection).</paragraph>
                        <paragraph>Decreased fetal survival and body weights in the presence of maternal toxicity (increased mortality) were noted when pregnant dams were administered intravenous bolus doses of 60 mg/kg epinephrine sulfate (approximately 12 times the MRHD based on body surface area) from GD 6 through Lactation Day 20. No adverse effects were noted at 10 mg/kg (1.9 times the MRHD). </paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0802">
                     <id root="b4058be1-4f46-8384-a01d-2ef3c6e28a70"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2	Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>A single published case report indicates that ephedrine is present in human milk. However, no information is available on the effects of the drug on the breastfed infant or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ephedrine sulfate injection and any potential adverse effects on the breastfed child from ephedrine sulfate injection or from the underlying maternal condition. </paragraph>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0804">
                     <id root="ebf8cf88-4b1b-3a5b-1d7b-4f9d76cb60b7"/>
                     <code code="34081-0" displayName="PEDIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.4  Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of ephedrine sulfate injection in pediatric patients have not been established.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Animal Toxicity Data</content>
                        </paragraph>
                        <paragraph>In a study in which juvenile rats were administered intravenous bolus doses of 2, 10, or 60 mg/kg ephedrine sulfate daily from Postnatal Day 35 to 56, an increased incidence of mortality was noted at the high dose of 60 mg/kg. The no-adverse-effect level was 10 mg/kg (approximately 1.9 times a maximum daily dose of 50 mg in a 60 kg person based on body surface area).</paragraph>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0805">
                     <id root="940c5e1d-5be8-3b1a-62db-22f0bf6c6b0b"/>
                     <code code="34082-8" displayName="GERIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.5  Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of ephedrine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
               <component>
                  <section ID="s_0806">
                     <id root="1ce4e772-5e1e-556a-c89e-743e15c10cb4"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.6	Renal Impairment</title>
                     <text>
                        <paragraph>Ephedrine and its metabolite are excreted in urine. In patients with renal impairment, excretion of ephedrine is likely to be affected with a corresponding increase in elimination half-life, which will lead to slow elimination of ephedrine and consequently prolonged pharmacological effect and potentially adverse reactions. Monitor patients with renal impairment carefully after the initial bolus dose for adverse events. </paragraph>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_1000">
               <id root="26429002-36a9-dbbe-a1d0-01d21dd6bc4b"/>
               <code code="34088-5" displayName="OVERDOSAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>10  OVERDOSAGE</title>
               <text>
                  <paragraph>Overdose of ephedrine can cause a rapid rise in blood pressure. In the case of an overdose, careful monitoring of blood pressure is recommended. If blood pressure continues to rise to an unacceptable level, parenteral antihypertensive agents can be administered at the discretion of the clinician.</paragraph>
               </text>
               <effectiveTime value="20220601"/>
            </section>
         </component>
         <component>
            <section ID="s_1100">
               <id root="116136cc-1b6d-0e45-2fbf-d0256e720881"/>
               <code code="34089-3" displayName="DESCRIPTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>11  DESCRIPTION</title>
               <text>
                  <paragraph>Ephedrine is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent. Ephedrine sulfate injection, USP is a clear, colorless, sterile solution for intravenous injection. It must be diluted before intravenous administration. The chemical name of ephedrine sulfate is benzenemethanol, α-[1-(methylamino)ethyl]-, [R-(R*,S*)]-, sulfate (2:1) (salt), and the molecular weight is 428.5 g/mol. Its structural formula is depicted below:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM160"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <br/>
                  <paragraph>
                     <br/>Ephedrine sulfate is freely soluble in water and methanol, slightly soluble in ethanol, very slightly soluble in chloroform, practically insoluble in ether. </paragraph>
                  <paragraph>Each mLof  the 50 mg/mL strength contains ephedrine sulfate, USP 50 mg (equivalent to 38 mg ephedrine base) in water for injection. The pH is adjusted with sodium hydroxide and/or glacial acetic acid if necessary. The pH range is 4.5 to 7.0.The 50 mg/mL vial must be diluted before intravenous administration.</paragraph>
               </text>
               <effectiveTime value="20220601"/>
               <component>
                  <observationMedia ID="MM160">
                     <text>structural formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="structural-formula.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_1200">
               <id root="70b53e4b-48e3-c0b2-c1ef-1653dda408a1"/>
               <code code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>12  CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20220601"/>
               <component>
                  <section ID="s_1201">
                     <id root="96505a44-2f4c-abd1-6e27-be26056b4964"/>
                     <code code="43679-0" displayName="MECHANISM OF ACTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.1  Mechanism of Action</title>
                     <text>
                        <paragraph>Ephedrine sulfate is a sympathomimetic amine that directly acts as an agonist at α- and β-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Pressor effects by direct alpha- and beta-adrenergic receptor activation are mediated by increases in arterial pressures, cardiac output, and peripheral resistance. Indirect adrenergic stimulation is caused by norepinephrine release from sympathetic nerves.</paragraph>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
               <component>
                  <section ID="s_1202">
                     <id root="d574f896-2fad-ba8d-9224-8d849376564a"/>
                     <code code="43681-6" displayName="PHARMACODYNAMICS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.2  Pharmacodynamics</title>
                     <text>
                        <paragraph>Ephedrine stimulates heart rate and cardiac output and variably increases peripheral resistance; as a result, ephedrine usually increases blood pressure. Stimulation of the α-adrenergic receptors of smooth muscle cells in the bladder base may increase the resistance to the outflow of urine. Activation of β-adrenergic receptors in the lungs promotes bronchodilation.</paragraph>
                        <paragraph>The overall cardiovascular effect from ephedrine is the result of a balance among α-1 adrenoceptor-mediated vasoconstriction, β-2 adrenoceptor-mediated vasoconstriction, and β-2 adrenoceptor-mediated vasodilatation. Stimulation of the β-1 adrenoceptors results in positive inotrope and chronotrope action.</paragraph>
                        <paragraph>Tachyphylaxis to the pressor effects of ephedrine may occur with repeated administration <content styleCode="italics">[see Warnings and Precautions<linkHtml href="#s_0502"> (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
               <component>
                  <section ID="s_1203">
                     <id root="c3cafa5d-bff5-2854-cf4a-9a63ee808868"/>
                     <code code="43682-4" displayName="PHARMACOKINETICS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.3  Pharmacokinetics</title>
                     <text>
                        <paragraph>Publications studying pharmacokinetics of oral administration of (-)-ephedrine support that (-)-ephedrine is metabolized into norephedrine. However, the metabolism pathway is unknown. Both the parent drug and the metabolite are excreted in urine. Limited data after IV administration of ephedrine support similar observations of urinary excretion of drug and metabolite. The plasma elimination half-life of ephedrine following oral administration was about 6 hours.</paragraph>
                        <paragraph>Ephedrine crosses the placental barrier <content styleCode="italics">[see Use in Specific Populations <linkHtml href="#s_0801">(8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_1300">
               <id root="44d55993-74d3-33f4-3dc2-6f00236e9c55"/>
               <code code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>13  NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20220601"/>
               <component>
                  <section ID="s_1301">
                     <id root="bd845a6c-1bd3-5264-3276-8e260bb7c1ed"/>
                     <code code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>: Two-year feeding studies in rats and mice conducted under the National Toxicology Program (NTP) demonstrated no evidence of carcinogenic potential with ephedrine sulfate at doses up to 10 mg/kg/day and 27 mg/kg/day (approximately 2 times and 3 times the maximum human recommended dose on a mg/m<sup>2</sup> basis, respectively).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>: Ephedrine sulfate tested negative in the in vitro bacterial reverse mutation assay, the in vitro mouse lymphoma assay, the in vitro sister chromatid exchange, the in vitro chromosomal aberration assay, and the in vivo rat bone marrow micronucleus assay.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>: There was no impact on fertility or early embryonic development in a study in which male rats were administered intravenous bolus doses of 0, 2, 10, or 60 mg/kg ephedrine sulfate (up to 12 times the maximum recommended human dose of 50 mg based on body surface area) for 28 days prior to mating and through gestation and females were treated for 14 days prior to mating through Gestation Day 7. </paragraph>
                     </text>
                     <effectiveTime value="20220601"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s_1400">
               <id root="79ea9d13-133e-569c-a6a2-db76b08dc0e6"/>
               <code code="34092-7" displayName="CLINICAL STUDIES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>14  CLINICAL STUDIES</title>
               <text>
                  <paragraph>The evidence for the efficacy of ephedrine injection is derived from the published literature. Increases in blood pressure following administration of ephedrine were observed in 14 studies, including 9 where ephedrine was used in pregnant women undergoing neuraxial anesthesia during Cesarean delivery, 1 study in non-obstetric surgery under neuraxial anesthesia, and 4 studies in patients undergoing surgery under general anesthesia. Ephedrine has been shown to raise systolic and mean blood pressure when administered as a bolus dose following the development of hypotension during anesthesia.</paragraph>
               </text>
               <effectiveTime value="20220601"/>
            </section>
         </component>
         <component>
            <section ID="s_1600">
               <id root="bace49cc-883a-0e0a-3b8a-760eb7e9e4e6"/>
               <code code="34069-5" displayName="HOW SUPPLIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>16  HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Ephedrine sulfate injection USP, 50 mg/mL, is supplied as follows:</paragraph>
                  <table styleCode="Noautorules" width="600">
                     <col align="left" width="30%"/>
                     <col align="left" width="18%"/>
                     <col align="left" width="52%"/>
                     <tbody>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">NDC</content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Strength</content>
                           </td>
                           <td styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">How Supplied</content>
                           </td>
                        </tr>
                        <tr valign="top">
                           <td styleCode="Toprule Botrule Lrule Rrule">43598-725-2550 mg/mL of ephedrine sulfateequivalent to 38 mg/mL of ephedrine base</td>
                           <td styleCode="Toprule Botrule Lrule Rrule">50 mg/mL of ephedrine sulfate equivalent to 38 mg/mL of ephedrine base</td>
                           <td styleCode="Toprule Botrule Lrule Rrule">1 mL fill in a 2 mL clear glass vial with purple flip-off cap; for single-dose (supplied in packages of 25) </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Vial stoppers are not manufactured with natural rubber latex. Store ephedrine sulfate injection USP, 50 mg/mL, at 20° to 25°C (68° to77°F) [see USP Controlled Room Temperature]. Store in carton until time of use. For single-dose only. Discard unused portion. </paragraph>
                  <br/>
                  <paragraph>Rx Only</paragraph>
                  <paragraph/>
                  <paragraph>Distributor: </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dr. Reddy’s Laboratories, Inc.</content>
                  </paragraph>
                  <paragraph>Princeton, NJ 08540</paragraph>
                  <paragraph>
                     <content styleCode="bold">Made in India</content>
                  </paragraph>
                  <br/>
                  <paragraph>Revised. 08/2023<br/>
                     <br/>
                     <renderMultiMedia referencedObject="MM727051641174"/>
                  </paragraph>
                  <br/>
               </text>
               <effectiveTime value="20220601"/>
            </section>
         </component>
         <component>
            <section ID="_b4834773-0450-7f39-bb86-65d168350b58">
               <id root="6f768c4b-7ed9-3188-9af1-85ed79129dc2"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION - Vial Label</title>
               <text>
                  <paragraph>NDC 43598-<content styleCode="bold">725</content>-11<br/>
                     <br/>
                     <content styleCode="bold">Ephedrine Sulfate <br/>Injection, USP <br/>50 mg/mL</content>
                     <br/>
                     <content styleCode="bold">For Intravenous Use</content>
                     <br/>
                     <content styleCode="bold">Must Be Diluted</content>
                     <br/>Discard unused portion <br/>1 mL Single-Dose Vial <br/>
                     <br/>Rx Only<br/>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM436378465215"/>
                  </paragraph>
               </text>
               <effectiveTime value="20220601"/>
            </section>
         </component>
         <component>
            <section ID="_489d6b4d-385e-0290-d96a-e5ae2caf7160">
               <id root="e5f01ee1-b062-114c-5adf-1e297652eff4"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION - Carton Label (25 Vials in 1 Carton)</title>
               <text>
                  <paragraph>NDC 43598-<content styleCode="bold">725</content>-25<br/>
                     <br/>
                     <content styleCode="bold">Ephedrine Sulfate Injection, USP <br/>50 mg/mL</content>
                     <br/>
                     <content styleCode="bold">For Intravenous Use</content>
                     <br/>
                     <content styleCode="bold">Must Be Diluted</content>
                     <br/>Discard unused portion <br/>25 x 1 mL Single-Dose Vials <br/>
                     <br/>Rx Only</paragraph>
                  <paragraph>
                     <br/>
                     <br/>
                     <renderMultiMedia referencedObject="pdp_02"/>
                  </paragraph>
                  <br/>
               </text>
               <effectiveTime value="20220601"/>
               <component>
                  <observationMedia ID="pdp_02">
                     <text>carton-label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="carton-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>